Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prednisolone sodium metasulfobenzoate is a synthetic glucocorticoid corticosteroid, used primarily as an anti-inflammatory and immunosuppressive agent. It is a salt form of prednisolone designed for improved delivery, including colon-targeted formulations (e.g. ATL-2502/Colal-Pred). Like other corticosteroids, it acts by binding to the **glucocorticoid receptor**, inhibiting pro-inflammatory signals and promoting anti-inflammatory effects. It is indicated for various inflammatory and autoimmune conditions such as asthma, ulcerative colitis, and other diseases where immune suppression or inflammation reduction is required[3][5][1]. The drug may be formulated in oral solid dosage forms such as tablets or granules[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on prednisolone sodium metasulfobenzoate.